Brilliant Violet 650™ anti-mouse CD83
Description
CD83 is a 45 kD type I transmembrane protein. It belongs to immunoglobulin superfamily and is expressed on mature dendritic cells and activated lymphocytes. CD83 is involved in the regulation of T cell development and immune response. Soluble form CD83 has been reported to inhibit dendritic cell maturation and dendritic cell-mediated T cell proliferation. Murine CD83 ligand has been found on B cells.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
References
1. Cramer SO, et al. 2000. Int. Immunol. 12:1347.
2. Fujimoto Y, et al. 2002. Cell 108:755.
3. Mott KR, et al. 2009. Virol J. 6:56. (FC) PubMed
4. Roland Cl, et al. 2009. Mol Cancer Res. 8:1761. (IHC) PubMed
5. Masuda Y, et al. 2010. Cancer Immunol Immunother. [Epub ahead of print] (FC) PubMed
6. Tze LE, et al. 2011. J Exp Med. PubMed
7. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed